Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma

Cancer Cell

Volumn 27, Issue 3, 2015, Pages 342-353

  Atwood, Scott X ^a   Sarin, Kavita Y ^a   Whitson, Ramon J ^a   Li, Jiang R ^a   Kim, Geurim ^a   Rezaee, Melika ^a   Ally, Mina S ^a   Kim, Jinah ^a   Yao, Catherine ^a   Chang, Anne Lynn S ^a   Oro, Anthony E ^a   Tang, Jean Y ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; VISMODEGIB; ANILIDE; G PROTEIN COUPLED RECEPTOR; PYRIDINE DERIVATIVE; SMO PROTEIN, HUMAN;

ARTICLE; BASAL CELL CARCINOMA; CANCER CELL; CANCER RESISTANCE; EXOME; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC VARIABILITY; LIGAND BINDING; MEDULLOBLASTOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; BINDING SITE; CARCINOMA, BASAL CELL; CHEMICAL STRUCTURE; CHEMISTRY; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; SKIN NEOPLASMS;

ERINACEIDAE;

ANILIDES; BINDING SITES; CARCINOMA, BASAL CELL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; EXOME; HEDGEHOG PROTEINS; HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN STRUCTURE, TERTIARY; PYRIDINES; RECEPTORS, G-PROTEIN-COUPLED; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84924242647     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.02.002     Document Type: Article

References (28)

1. Amakye D., Jagani Z., Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat. Med. 2013, 19:1410-1422.
2. Atwood S.X., Chang A.L., Oro A.E. Hedgehog pathway inhibition and the race against tumor evolution. J.Cell Biol. 2012, 199:193-197.
3. Atwood S.X., Li M., Lee A., Tang J.Y., Oro A.E. GLI activation by atypical protein kinase C ι/λ regulates the growth of basal cell carcinomas. Nature 2013, 494:484-488.
4. Axelson M., Liu K., Jiang X., He K., Wang J., Zhao H., Kufrin D., Palmby T., Dong Z., Russell A.M., et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin. Cancer Res. 2013, 19:2289-2293.
5. Ayers K.L., Thérond P.P. Evaluating Smoothened as a G-protein-coupled receptor for Hedgehog signalling. Trends Cell Biol. 2010, 20:287-298.
6. Buonamici S., Williams J., Morrissey M., Wang A., Guo R., Vattay A., Hsiao K., Yuan J., Green J., Ospina B., et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2010, 2:51ra70.
7. Chang A.L., Oro A.E. Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch. Dermatol. 2012, 148:1324-1325.
8. Dey J., Ditzler S., Knoblaugh S.E., Hatton B.A., Schelter J.M., Cleary M.A., Mecham B., Rorke-Adams L.B., Olson J.M. A distinct Smoothened mutation causes severe cerebellar developmental defects and medulloblastoma in a novel transgenic mouse model. Mol. Cell. Biol. 2012, 32:4104-4115.
9. Dijkgraaf G.J., Alicke B., Weinmann L., Januario T., West K., Modrusan Z., Burdick D., Goldsmith R., Robarge K., Sutherlin D., et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011, 71:435-444.
10. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., Jia M., Shepherd R., Leung K., Menzies A., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011, 39:D945-D950.
11. Gajjar A., Stewart C.F., Ellison D.W., Kaste S., Kun L.E., Packer R.J., Goldman S., Chintagumpala M., Wallace D., Takebe N., et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin. Cancer Res. 2013, 19:6305-6312.
12. Huang da W., Sherman B.T., Zheng X., Yang J., Imamichi T., Stephens R., Lempicki R.A. Extracting biological meaning from large gene lists with DAVID. Curr. Protoc. Bioinformatics 2009, Chapter 13. Unit 13.11.
13. Jayaraman S.S., Rayhan D.J., Hazany S., Kolodney M.S. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J.Invest. Dermatol. 2014, 134:213-220.
14. Katritch V., Cherezov V., Stevens R.C. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 2013, 53:531-556.
15. Kim J., Aftab B.T., Tang J.Y., Kim D., Lee A.H., Rezaee M., Kim J., Chen B., King E.M., Borodovsky A., et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013, 23:23-34.
16. Kool M., Jones D.T., Jäger N., Northcott P.A., Pugh T.J., Hovestadt V., Piro R.M., Esparza L.A., Markant S.L., Remke M., et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 2014, 25:393-405. ICGC PedBrain Tumor Project.
17. Metcalfe C., Alicke B., Crow A., Lamoureux M., Dijkgraaf G.J., Peale F., Gould S.E., de Sauvage F.J. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition. Cancer Res. 2013, 73:7034-7042.
18. Mortazavi A., Williams B.A., McCue K., Schaeffer L., Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 2008, 5:621-628.
19. Reifenberger J., Wolter M., Knobbe C.B., Köhler B., Schönicke A., Scharwächter C., Kumar K., Blaschke B., Ruzicka T., Reifenberger G. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br. J. Dermatol. 2005, 152:43-51.
20. Riobo N.A., Saucy B., Dilizio C., Manning D.R. Activation of heterotrimeric G proteins by Smoothened. Proc. Natl. Acad. Sci. USA 2006, 103:12607-12612.
21. Rogers H.W., Weinstock M.A., Harris A.R., Hinckley M.R., Feldman S.R., Fleischer A.B., Coldiron B.M. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch. Dermatol. 2010, 146:283-287.
22. Sekulic A., Migden M.R., Oro A.E., Dirix L., Lewis K.D., Hainsworth J.D., Solomon J.A., Yoo S., Arron S.T., Friedlander P.A., et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N.Engl. J. Med. 2012, 366:2171-2179.
23. Tang J.Y., Mackay-Wiggan J.M., Aszterbaum M., Yauch R.L., Lindgren J., Chang K., Coppola C., Chanana A.M., Marji J., Bickers D.R., Epstein E.H. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N.Engl. J. Med. 2012, 366:2180-2188.
24. Tang Y., Gholamin S., Schubert S., Willardson M.I., Lee A., Bandopadhayay P., Bergthold G., Masoud S., Nguyen B., Vue N., et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat. Med. 2014, 20:732-740.
25. Wang Y., Ding Q., Yen C.-J., Xia W., Izzo J.G., Lang J.-Y., Li C.-W., Hsu J.L., Miller S.A., Wang X., et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 2012, 21:374-387.
26. Wang C., Wu H., Katritch V., Han G.W., Huang X.P., Liu W., Siu F.Y., Roth B.L., Cherezov V., Stevens R.C. Structure of the human smoothened receptor bound to an antitumour agent. Nature 2013, 497:338-343.
27. Xie J., Murone M., Luoh S.M., Ryan A., Gu Q., Zhang C., Bonifas J.M., Lam C.W., Hynes M., Goddard A., et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998, 391:90-92.
28. Yauch R.L., Dijkgraaf G.J., Alicke B., Januario T., Ahn C.P., Holcomb T., Pujara K., Stinson J., Callahan C.A., Tang T., et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326:572-574.